Navigation Links
Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
Date:5/3/2011

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that several members of management will speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing.  The conference is taking place May 8-11, 2011 at the Toronto Convention Center.  

  • James Levine, President and Chief Executive Officer, will make opening remarks at a plenary breakfast, What Consumers and Manufacturers Need from Industrial Biotech Companies: A Customer Perspective on Tuesday, May 10th at 7:00 am.
  • Janet Roemer, Chief Operating Officer, will be moderating a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, on Wednesday, May 11th at 11:00 am. Roemer will also be speaking on a panel, The Power of Enzymes, Tuesday, May 10th at 3:00 pm
  • Ken Barrett, Vice President, Business Development, will be moderating a panel, Protein Engineering and Screening Methods, Tuesday, May 10th at 9:00 am.
  • David Weiner, Ph.D., Vice President, R&D Strategy and Partnerships, will be speaking on a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, Wednesday, May 11th at 11:00 am.

  • The Company will also have a booth at space 316 in the Toronto Convention Center.

    For more information on the BIO Industrial Biotechnology Conference please visit http://www.bio.org/worldcongress/index.asp

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

    Vice President, Corporate Communications

    858-431-8580

    kelly.lindenboom@verenium.com

    Sarah Carmody

    Manager, Corporate Communications

    858-431-8581

    sarah.carmody@verenium.com
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
    (Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
    (Date:2/16/2017)... 16, 2017  Rhythm, a biopharmaceutical company ... that result in life-threatening metabolic disorders, today ... mezzanine round of financing with existing investors ... New Enterprise Associates, Pfizer Venture Investments, Third ... investment fund. Rhythm will use the proceeds ...
    (Date:2/15/2017)... 15. Februar 2017  Trianni, Inc. („TRIANNI") gab ... (Janssen) eine Lizenzvereinbarung über die Verwendung der The ... Plattform für die Entdeckung monoklonaler Antikörper. ... chimäres Gensegmentdesign aus, das Janssen den Zugang ... bietet und das für die schelle Isolierung vollständig ...
    Breaking Biology Technology:
    (Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
    (Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
    (Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
    Breaking Biology News(10 mins):